Anebulo Pharmaceuticals, Inc.

Q: Dec 31 2025

Q: Sep 30 2025

FY: Jun 30 2025

Q: Mar 31 2025

Q: Dec 31 2024

Q: Sep 30 2024

FY: Jun 30 2024

Q: Mar 31 2024

Q: Dec 31 2023

Q: Sep 30 2023

FY: Jun 30 2023

Q: Mar 31 2023

Q: Dec 31 2022

Q: Sep 30 2022

FY: Jun 30 2022

Q: Mar 31 2022

Q: Dec 31 2021

Q: Sep 30 2021

FY: Jun 30 2021

Q: Mar 31 2021

Results of Operations and Financial Condition

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Other Events

Other Events

Other Events

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Other Events

Other Events

Results of Operations and Financial Condition

Other Events

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Entry into a Material Definitive Agreement

Results of Operations and Financial Condition

Other Events

Entry into a Material Definitive Agreement

2.02,9.01

Regulation FD Disclosure

2.02,9.01

Certification of termination of registration of a class of securities (Section 12(g))

Post Effective Amendment to S-8

Post Effective Amendment to S-8

Notice of Effectiveness

Notice of Effectiveness

Post-effective amendment to a registration statement

Post-effective amendment to a registration statement

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Registration statement under Securities Act of 1933

<ITEMS>06b

Notice of Effectiveness

Registration (IPO) statement under Securities Act of 1933

06b

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement with Pricing Information

Certification of approval for listing and registration on a national securities exchange

Notice of Effectiveness

Amended Initial Registration Statement

No description available

No description available

Preliminary Proxy Statement

Definitive Proxy Statement

Preliminary Proxy Statement

Definitive Proxy Statement

Preliminary Proxy Statement

Required Information in Proxy Statement

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Nantahala Capital Management, LLC

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

Aryeh Jason

Kupchyk Areta

English Aron R.

SHAH BIMAL R.

Cundy Kenneth C

Lin Kenneth

Lawler Joseph F.

Calloway Nathaniel

Cunningham, Richard Anthony

MANGROVE PARTNERS IM, LLC

English Aron R.

Notification of the removal from listing and registration of matured redeemed or retired securities

Correspondence with the SEC

Annual Report Scanned (Paper)

Correspondence with the SEC

Letter from the SEC

Annual Report Scanned (Paper)

Letter from the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Draft registration statement (confidential submission) (amendment)

No description available

Letter from the SEC

Draft registration statement (confidential submission)